

AMENDMENTS TO THE CLAIMS


Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition ~~having ER α agonist activity and having ER β antagonist activity~~, comprising:

a steroid compound ~~satisfying the following~~ of the structural formula:



formula I


wherein:

one of X and Y is OH, the other being H;

R₃ is H or COR'₃, with R'₃ being alkyl or aryl;

R₇, R₁₆, and R₁₇ each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl;

R₁₁ is selected from the group consisting of




and

a pharmaceutical acceptable auxiliary, wherein the compound of formula I possesses ER α agonist activity and having ER β antagonist activity.

2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled).
6. (Cancelled).
7. (Previously Presented) A method for treating estrogen deficiency disorders, comprising:
administering to a patient afflicted with an estrogen deficiency disorder a therapeutically effective amount of the pharmaceutical composition of claim 1.
8. (Currently Amended) A method of treating estrogen deficiency disorders by inducing ER α agonist activity and ER β antagonist activity in a patient in need thereof, comprising:

administering a therapeutically effective amount of a steroid compound satisfying the following structural formula:




wherein:

one of X and Y is OH, the other being H;

R₃ is H or COR'₃, with R'₃ being alkyl or aryl;

R₇, R₁₆, and R₁₇ each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl;


R₁₁ is selected from the group consisting of



9. (Canceled).

10. (Canceled).

11. (Canceled).
12. (Canceled).
13. (Currently Amended) A steroid compound ~~having ER α agonist activity and having ER β antagonist activity and satisfying the following~~ of the structural formula:




wherein:

one of X and Y is OH, the other being H;

R₃ is H or COR'₃, with R'₃ being alkyl or aryl;

R₇, R₁₆, and R₁₇ each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl; R₁₁ is selected from the group consisting of



wherein the compound of formula I possesses ER α agonist activity and ER β antagonist activity.

Application No. 09/831,954
Amendment dated October 26, 2007
Reply to Office Action of May 2, 2007

Docket No.: 1998.414US

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)